Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries Limited : The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Teva Pharmaceutical Industries Ltd. Shareholders and a Lead Plaintiff Deadline of October 23, 2017 (TEVA)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 05:23pm CET

NEW YORK, NY / ACCESSWIRE / October 4, 2017 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) who purchased American Depositary Shares between November 15, 2016 and August 2, 2017. The action, which was filed in the United States District Court for the Eastern District of Pennsylvania, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that, throughout the Class Period, Defendants issued materially false and/or misleading statements and/or failed to disclose adverse information concerning the Company's business and outlook. In particular, it is alleged that Teva failed to disclose and/or omitted the true negative impact of the acquisition and integration of Actavis Generics on the Company's financial results and business prospects.

Shareholders have until October 23, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/teva-pharmaceutical-industries-ltd?wire=1.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
06:36p TEVA PHARMACEUTICAL INDUSTRIES : Gains on Workforce Reductions
06:09p TEVA PHARMACEUTICAL INDUSTRIES : Riots outside Teva's Jerusalem factory over mas..
04:44p TEVA PHARMACEUTICAL INDUSTRIES : Pharm to lay off a quarter of workforce, suspen..
04:17p TEVA PHARMACEUTICAL INDUSTRIES : to layoff 25% of its global workforce by end of..
03:11pDJTEVA PHARMACEUTICAL INDUSTRIES : to Cut 14,000 Jobs, Suspend Dividend -- Update
02:14p PM TO CEO OF DRUG GIANT : Minimize harm to workers
02:13p TEVA PHARMACEUTICAL INDUSTRIES LTD ( : Today’s Research Reports on Stocks to Wat..
02:01pDJTEVA PHARMACEUTICAL INDUSTRIES : to Cut 14,000 Jobs
01:18p TEVA PHARMACEUTICAL INDUSTRIES : Israeli drugmaker Teva to cut quarter of global..
01:04p TEVA PHARMACEUTICAL INDUSTRIES : Announces Restructuring Plan and Additional Mea..
More news
News from SeekingAlpha
01:41p Analysts weigh in on Teva's restructuring plan
01:20p Moody's to review Teva's rating for possible downgrade
11:00a HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
09:17a PREMARKET GAINERS AS OF 9 : 05 am
07:24a Teva to cut workforce 25%, suspends dividend; shares up 3% premarket
Financials ($)
Sales 2017 22 633 M
EBIT 2017 6 276 M
Net income 2017 -
Debt 2017 34 419 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,23x
EV / Sales 2018 2,12x
Capitalization 15 987 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 24,5 $
Spread / Average Target 54%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Michael R. Hayden Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-59.51%15 987
JOHNSON & JOHNSON21.53%383 877
NOVARTIS12.01%221 304
PFIZER10.04%218 400
ROCHE HOLDING LTD.3.40%210 833
MERCK AND COMPANY-6.96%155 214